The University of Southampton
University of Southampton Institutional Repository

#872 malignant ovarian germ cell tumours: an international multicentre study to identify new prognostic risk factors

#872 malignant ovarian germ cell tumours: an international multicentre study to identify new prognostic risk factors
#872 malignant ovarian germ cell tumours: an international multicentre study to identify new prognostic risk factors
Introduction/background: malignant ovarian germ cell tumours (MOGCTs) are rare and aggressive malignancies mainly affecting young women. Unlike testicular GCTs, prognostic factors are poorly understood, but small series have most consistently suggested that advanced stage best predicts worse outcomes. Here, we examine a large, international patient series to identify new adverse prognostic factors.

Methodology: we evaluated 254 patients treated in Charing Cross Hospital and Mount Vernon Cancer Centre, UK and in Multi-centre Italian Trials in Ovarian Cancer (MITO) group between 1971 and 2018. Descriptive statistical, survival and Cox regression techniques were performed using STATA (StataCorp, v.16, Texas, USA).

Results: median age was 26 years (IQR, 20–32). There were 22.4% dysgerminomas, 18.5% immature teratomas, 33.5% yolk sac, 17.7% mixed, 1.2% embryonal, 2.4% choriocarcinoma and 4.3% unclassified. FIGO stage distribution was 31.5% (IC/M), 12.6% (II), 40.5% (III) and 15.4% (IV). First line chemotherapy consisted of BEP, POMB/ACE or other regimens for 48.0%, 42.5% and 9.5% of patients, respectively. Recurrences received high dose chemotherapy (HDCT), conventional chemotherapy ± surgery, and surgery alone in 24.4%, 65.9% and 7.3% of cases.
At multivariable analysis, age ≥35 at presentation [HR 2.3, 95%CI (1.0–5.0), p=0.04], stage [HR 1.5, 95%CI (1.0–2.1), p=0.032], and non-dysgerminoma versus dysgerminoma [HR 12.7, 95%CI (1.7–94.0), p=0.013] were significantly associated with worse cancer-specific survival (CSS). Twenty-year CSS for stage IC/M, II, III, and IV were 94.8%, 82.3%, 83.2% and 84.3%, respectively. In patients relapsing or failing to achieve a complete response, HDCT showed a trend for improved 5-year CSS compared to conventional treatments [HR 0.5, 95%CI (0.2–1.5), p=0.241].

Conclusion: this study demonstrated that in addition to advanced stage, age ≥35 years, and non-dysgerminoma, but not immature teratomas, are independent adverse prognostic factors for CSS. Strikingly, stage IV disease can still achieve >80% long-term survival rates. HDCT may improve outcomes for relapsing/incomplete responding patients.
1048-891X
A28-A29
Suyanto, Suyanto
6dcfbabf-8279-4496-bed0-0f9c9248a4b3
Bergamini, Alice
f71e5a5a-51cc-40da-97dc-15c4e971c28b
Savva, Constantinos
33110108-fcc0-463a-8532-ef32e1e084ce
Kaur, Baljeet
fa9cd317-54e0-45b5-a7df-e37a1910973d
Saso, Srdjan
2db60c99-3447-4056-a133-09108b9bb02a
Fotopoulou, Christina
fe7287d9-c0f0-4f19-b40f-b126ad47064e
Sarwar, Naveed
0507a5e9-ca62-4dc9-9b56-45968fccbf12
Lim, Adrian
8ad4cf5a-9e32-49f5-9ca1-edd6cdae54ed
Rustin, Gordon
a8488e7b-8094-472a-b7f8-9aa462cd5c42
Sharma, Anand
a56f46e7-b293-4dfb-a680-2d53ff8fe8cc
Hall, Marcia
041132f8-3f24-443c-a223-9150487713c8
Gogbashian, Andrew
24f1f90d-f420-4fe8-93e9-41d633de0a82
Camnasio, Cristina Angela
c7c8d59a-c321-4540-9e54-8ad4ef0416e2
Merrick, Sophie
9c3bc221-768c-408e-bbe5-0b447eb03f38
Cassani, Chiara
d9e8872e-f00d-4dd0-b854-1022e0bb4042
Pignata, Sandro
66a4c2b8-7f19-4bbd-82f8-da59a4599378
Gennaro, Cormio
91eaf89a-9e70-4115-a7db-d2cb470efab0
Ferrandina, Gabriella
e5a60ddb-35b2-4933-b0dd-85d17cdc6354
Scarfone, Giovanna
cba5cb72-4cdd-434f-86fd-998275462aac
Mangili, Giorgia
01be669b-198f-42ac-a6ff-6a25cef9eeac
Seckl, Michael
4efdb7c7-29b8-48d0-b2ca-2c8298cf3680
et al.
Suyanto, Suyanto
6dcfbabf-8279-4496-bed0-0f9c9248a4b3
Bergamini, Alice
f71e5a5a-51cc-40da-97dc-15c4e971c28b
Savva, Constantinos
33110108-fcc0-463a-8532-ef32e1e084ce
Kaur, Baljeet
fa9cd317-54e0-45b5-a7df-e37a1910973d
Saso, Srdjan
2db60c99-3447-4056-a133-09108b9bb02a
Fotopoulou, Christina
fe7287d9-c0f0-4f19-b40f-b126ad47064e
Sarwar, Naveed
0507a5e9-ca62-4dc9-9b56-45968fccbf12
Lim, Adrian
8ad4cf5a-9e32-49f5-9ca1-edd6cdae54ed
Rustin, Gordon
a8488e7b-8094-472a-b7f8-9aa462cd5c42
Sharma, Anand
a56f46e7-b293-4dfb-a680-2d53ff8fe8cc
Hall, Marcia
041132f8-3f24-443c-a223-9150487713c8
Gogbashian, Andrew
24f1f90d-f420-4fe8-93e9-41d633de0a82
Camnasio, Cristina Angela
c7c8d59a-c321-4540-9e54-8ad4ef0416e2
Merrick, Sophie
9c3bc221-768c-408e-bbe5-0b447eb03f38
Cassani, Chiara
d9e8872e-f00d-4dd0-b854-1022e0bb4042
Pignata, Sandro
66a4c2b8-7f19-4bbd-82f8-da59a4599378
Gennaro, Cormio
91eaf89a-9e70-4115-a7db-d2cb470efab0
Ferrandina, Gabriella
e5a60ddb-35b2-4933-b0dd-85d17cdc6354
Scarfone, Giovanna
cba5cb72-4cdd-434f-86fd-998275462aac
Mangili, Giorgia
01be669b-198f-42ac-a6ff-6a25cef9eeac
Seckl, Michael
4efdb7c7-29b8-48d0-b2ca-2c8298cf3680

Suyanto, Suyanto, Bergamini, Alice and Savva, Constantinos , et al. (2025) #872 malignant ovarian germ cell tumours: an international multicentre study to identify new prognostic risk factors. International Journal of Gynecologic Cancer, 33 (Suppl. 3), A28-A29. (doi:10.1136/ijgc-2023-esgo.42).

Record type: Meeting abstract

Abstract

Introduction/background: malignant ovarian germ cell tumours (MOGCTs) are rare and aggressive malignancies mainly affecting young women. Unlike testicular GCTs, prognostic factors are poorly understood, but small series have most consistently suggested that advanced stage best predicts worse outcomes. Here, we examine a large, international patient series to identify new adverse prognostic factors.

Methodology: we evaluated 254 patients treated in Charing Cross Hospital and Mount Vernon Cancer Centre, UK and in Multi-centre Italian Trials in Ovarian Cancer (MITO) group between 1971 and 2018. Descriptive statistical, survival and Cox regression techniques were performed using STATA (StataCorp, v.16, Texas, USA).

Results: median age was 26 years (IQR, 20–32). There were 22.4% dysgerminomas, 18.5% immature teratomas, 33.5% yolk sac, 17.7% mixed, 1.2% embryonal, 2.4% choriocarcinoma and 4.3% unclassified. FIGO stage distribution was 31.5% (IC/M), 12.6% (II), 40.5% (III) and 15.4% (IV). First line chemotherapy consisted of BEP, POMB/ACE or other regimens for 48.0%, 42.5% and 9.5% of patients, respectively. Recurrences received high dose chemotherapy (HDCT), conventional chemotherapy ± surgery, and surgery alone in 24.4%, 65.9% and 7.3% of cases.
At multivariable analysis, age ≥35 at presentation [HR 2.3, 95%CI (1.0–5.0), p=0.04], stage [HR 1.5, 95%CI (1.0–2.1), p=0.032], and non-dysgerminoma versus dysgerminoma [HR 12.7, 95%CI (1.7–94.0), p=0.013] were significantly associated with worse cancer-specific survival (CSS). Twenty-year CSS for stage IC/M, II, III, and IV were 94.8%, 82.3%, 83.2% and 84.3%, respectively. In patients relapsing or failing to achieve a complete response, HDCT showed a trend for improved 5-year CSS compared to conventional treatments [HR 0.5, 95%CI (0.2–1.5), p=0.241].

Conclusion: this study demonstrated that in addition to advanced stage, age ≥35 years, and non-dysgerminoma, but not immature teratomas, are independent adverse prognostic factors for CSS. Strikingly, stage IV disease can still achieve >80% long-term survival rates. HDCT may improve outcomes for relapsing/incomplete responding patients.

Text
1-s2.0-S1048891X2410597X-main - Version of Record
Download (832kB)

More information

e-pub ahead of print date: 1 September 2023
Published date: 30 January 2025

Identifiers

Local EPrints ID: 501580
URI: http://eprints.soton.ac.uk/id/eprint/501580
ISSN: 1048-891X
PURE UUID: 1440c5e5-dd8f-446f-be3d-64a41701261e
ORCID for Constantinos Savva: ORCID iD orcid.org/0000-0003-0805-4719

Catalogue record

Date deposited: 04 Jun 2025 16:30
Last modified: 21 Aug 2025 05:03

Export record

Altmetrics

Contributors

Author: Suyanto Suyanto
Author: Alice Bergamini
Author: Constantinos Savva ORCID iD
Author: Baljeet Kaur
Author: Srdjan Saso
Author: Christina Fotopoulou
Author: Naveed Sarwar
Author: Adrian Lim
Author: Gordon Rustin
Author: Anand Sharma
Author: Marcia Hall
Author: Andrew Gogbashian
Author: Cristina Angela Camnasio
Author: Sophie Merrick
Author: Chiara Cassani
Author: Sandro Pignata
Author: Cormio Gennaro
Author: Gabriella Ferrandina
Author: Giovanna Scarfone
Author: Giorgia Mangili
Author: Michael Seckl
Corporate Author: et al.

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×